cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alector Inc
16 own
8 watching
Current Price
$5.82
$-0.01
(-0.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
481.25M
52-Week High
52-Week High
9.06500
52-Week Low
52-Week Low
3.66000
Average Volume
Average Volume
0.26M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization481.25M
icon52-Week High9.06500
icon52-Week Low3.66000
iconAverage Volume0.26M
iconDividend Yield--
iconP/E Ratio--
What does the Alector Inc do?
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More
How much money does Alector Inc make?
News & Events about Alector Inc.
Tickeron - Stocks
1 year ago
This is a signal that ALEC's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Ticker Report
1 year ago
Alector (NASDAQ:ALEC Get Rating) had its target price reduced by Citigroup from $17.00 to $12.00 in a research report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. ALEC has been the topic of a number of other research reports. Morgan Stanley dropped ...
Globe Newswire
1 year ago
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimers disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN, a key regulator of immune activity and lysosomal function in ...
Zolmax
1 year ago
Shares of Alector, Inc. (NASDAQ:ALEC Get Rating) have received an average recommendation of Hold from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating ...
Ticker Report
1 year ago
Shares of Alector, Inc. (NASDAQ:ALEC Get Rating) have received a consensus rating of Hold from the eight research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold ...
Frequently Asked Questions
Frequently Asked Questions
What is Alector Inc share price today?
plus_minus_icon
Can Indians buy Alector Inc shares?
plus_minus_icon
How can I buy Alector Inc shares from India?
plus_minus_icon
Can Fractional shares of Alector Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Alector Inc stocks?
plus_minus_icon
What is today’s traded volume of Alector Inc?
plus_minus_icon
What is today’s market capitalisation of Alector Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Alector Inc?
plus_minus_icon
What percentage is Alector Inc down from its 52-Week High?
plus_minus_icon
What percentage is Alector Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.82
$-0.01
(-0.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00